Phillips Medisize has acquired the complete footprint of its Chippenham site in England, as reported by Fierce Pharma, adding laboratory and cleanroom capacity and giving pharmaceutical developers a longer-term, company-controlled UK base for inhalation programmes; financial terms were not disclosed, according to Investors in Healthcare.

According to the company announcement, Chippenham and the Cambridge site form the Global Inhalation Center of Excellence, supporting dry powder inhalers and nebulisers with powder and liquid formulation, spray drying, powder blending, analytical testing, technology transfer and clinical supply manufacturing.

BioSpace, carrying the company’s release, reported that the footprint is about 634,670 square feet and gives long-term operational control to broaden formulation development and clinical trial supplies manufacturing.

The Hudson Star-Observer reported that the expansion builds on the 2025 acquisition of Vectura Group, and that Phillips Medisize has 30 locations, including 23 production facilities and seven R&D centres.

Phillips Medisize is a Molex company that designs, develops, engineers and manufactures pharmaceutical drug delivery, in vitro diagnostic and medtech devices, headquartered in Hudson, Wisconsin, according to the announcement, and Molex is a global electronics group that has owned it since 2016, per Investors in Healthcare.

Charlie Schumacher, vice president of inhalation therapies at Phillips Medisize, said in the company announcement that inhalation revenue is projected to grow substantially over five years, so securing the full site provides dedicated talent, laboratories and cleanroom capacity from feasibility to commercial scale-up.

The purchase reflects drug-device contract manufacturers securing owned sites for inhalation work, with dry powder inhalers and nebulisers needing laboratory and cleanroom capacity alongside formulation expertise, according to the announcement.

Research and Markets estimates the inhalation CDMO market at $2.35bn in 2026, growing 6.6 per cent a year to $3.03bn by 2030, with increased outsourcing by pharmaceutical companies among the drivers.

For the sector, Contract Pharma’s report of Molex closing the Vectura acquisition in January 2025 puts the Chippenham purchase in context: an acquirer converting inherited capacity into long-term owned infrastructure.

The wider signal for the sector is that inhalation capability is being built as end-to-end sites covering formulation, device and clinical supply, rather than as separate services.